SUNIL AGARWAL
CIK 1616640 · EVP, Head of Development & CMO · last filed 2026-01-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.41M
Companies
7
Total Filings
53
Lifetime Open-Market Net
-$4.28M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Astria Therapeutics, Inc. (ATXS) Delisted | Director | — | $12.58 | — | $0 | 3 | 2026-01-23 |
| ARVN | Director | 30,166 | $8.06 | $243.1K | $0 | 3 | 2025-06-30 |
| Calithera Biosciences, Inc. (CALA) Delisted | Director | — | $0.00 | — | $0 | 8 | 2022-06-03 |
| SANA | EVP, Head of Development & CMO | 1,551,627 | $3.18 | $4.93M | -$1.56M | 4 | 2022-03-08 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 2,300 | — | — | $0 | 8 | 2020-06-23 |
| Juno Therapeutics, Inc. (JUNO) Delisted | President of R & D | 35,893 | — | — | -$326.1K | 5 | 2018-03-07 |
| RARE | Chief Medical Officer | 9,136 | $25.02 | $228.6K | -$2.39M | 21 | 2016-08-23 |
Recent Filings · Page 6 of 6
53 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2015-08-21 | RARE | Mixed | −12,500 | -$1.97M | EDGAR |
| 2015-05-27 | RARE | Grant (A) | +4,400 | $0 | EDGAR |
| 2014-08-21 | RARE | Grant (A) | +25,000 | $0 | EDGAR |
Showing 51–53 of 53
Prev
Page 6 of 6
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.